The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy
Background and Objective: Central serous retinopathy (CSR) is an idiopathic retinal disease that causes visual impairment and metamorphopsia. Due to the unknown etiology of CSR, the present study was conducted to investigate the role of metabolic disorders such as hyperlipidemia, diabetes, hypothyro...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Babol University of Medical Sciences
2022-03-01
|
| Series: | Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul |
| Subjects: | |
| Online Access: | http://jbums.org/article-1-10814-en.html |
| _version_ | 1828177991509737472 |
|---|---|
| author | M Babaei H Shirafkan SA Rasoulinejad |
| author_facet | M Babaei H Shirafkan SA Rasoulinejad |
| author_sort | M Babaei |
| collection | DOAJ |
| description | Background and Objective: Central serous retinopathy (CSR) is an idiopathic retinal disease that causes visual impairment and metamorphopsia. Due to the unknown etiology of CSR, the present study was conducted to investigate the role of metabolic disorders such as hyperlipidemia, diabetes, hypothyroidism, and hypertension (as a cardiovascular disease) in the treatment outcome of CSR patients.
Methods: This cross-sectional study was performed on 55 CSR patients whose problem was approved by ophthalmologic examinations in the Ophthalmology center of Ayatollah Rouhani Hospital, Babol, Iran. The patients were then treated with intravitreal injection of 1.25 mg/0.05 ml bevacizumab (Avastin®) 3 to 4 millimeters away from limbus under sterile conditions. Based on having and not having hypertension, diabetes, hypothyroidism and obesity, all patients underwent ophthalmological examination, including visual acuity (VA) and central macular thickness (CMT) by optical coherence tomography (OCT) before injection and one month after that.
Findings: The mean age of CSR patients (32 men and 23 women) was 42±11.50 years. After treatment, the CMT value in hypertensive patients (328.66±34.00 µm) was significantly higher than non-hypertensive patients (302.56±41.79) (p=0.025). The CMT value after treatment was considerably lower in non-diabetic patients (306.08±42.49 µm) compared to diabetic patients (336.77±17.42 µm) (p=0.039). Neither VA nor CMT was significantly different between hyperlipidemic patients and non-hyperlipidemic patients. In addition, there were no significant differences in VA and CMT between patients with hypothyroidism and without hypothyroidism.
Conclusion: The results of this study showed that hypertension and diabetes are important factors in CSR patients’ response to bevacizumab injection. |
| first_indexed | 2024-04-12T05:07:03Z |
| format | Article |
| id | doaj.art-8a0fe6aad4b940d7bdd5274332c85b0b |
| institution | Directory Open Access Journal |
| issn | 1561-4107 2251-7170 |
| language | English |
| last_indexed | 2024-04-12T05:07:03Z |
| publishDate | 2022-03-01 |
| publisher | Babol University of Medical Sciences |
| record_format | Article |
| series | Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul |
| spelling | doaj.art-8a0fe6aad4b940d7bdd5274332c85b0b2022-12-22T03:46:50ZengBabol University of Medical SciencesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul1561-41072251-71702022-03-01241265273The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous RetinopathyM Babaei0H Shirafkan1SA Rasoulinejad2 1.Clinical Research Development Unite of Rouhani Hospital, Babol University of Medical Sciences, Babol, I.R.Iran. 2.Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran. 3.Department of Ophthalmology, School of Medicine, Babol University of Medical Sciences, Babol, I.R.Iran. Background and Objective: Central serous retinopathy (CSR) is an idiopathic retinal disease that causes visual impairment and metamorphopsia. Due to the unknown etiology of CSR, the present study was conducted to investigate the role of metabolic disorders such as hyperlipidemia, diabetes, hypothyroidism, and hypertension (as a cardiovascular disease) in the treatment outcome of CSR patients. Methods: This cross-sectional study was performed on 55 CSR patients whose problem was approved by ophthalmologic examinations in the Ophthalmology center of Ayatollah Rouhani Hospital, Babol, Iran. The patients were then treated with intravitreal injection of 1.25 mg/0.05 ml bevacizumab (Avastin®) 3 to 4 millimeters away from limbus under sterile conditions. Based on having and not having hypertension, diabetes, hypothyroidism and obesity, all patients underwent ophthalmological examination, including visual acuity (VA) and central macular thickness (CMT) by optical coherence tomography (OCT) before injection and one month after that. Findings: The mean age of CSR patients (32 men and 23 women) was 42±11.50 years. After treatment, the CMT value in hypertensive patients (328.66±34.00 µm) was significantly higher than non-hypertensive patients (302.56±41.79) (p=0.025). The CMT value after treatment was considerably lower in non-diabetic patients (306.08±42.49 µm) compared to diabetic patients (336.77±17.42 µm) (p=0.039). Neither VA nor CMT was significantly different between hyperlipidemic patients and non-hyperlipidemic patients. In addition, there were no significant differences in VA and CMT between patients with hypothyroidism and without hypothyroidism. Conclusion: The results of this study showed that hypertension and diabetes are important factors in CSR patients’ response to bevacizumab injection.http://jbums.org/article-1-10814-en.htmlcentral serous chorioretinopathybevacizumabvisual acuityoptical coherence tomography. |
| spellingShingle | M Babaei H Shirafkan SA Rasoulinejad The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul central serous chorioretinopathy bevacizumab visual acuity optical coherence tomography. |
| title | The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy |
| title_full | The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy |
| title_fullStr | The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy |
| title_full_unstemmed | The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy |
| title_short | The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy |
| title_sort | effect of metabolic diseases on the outcome of bevacizumab injection for central serous retinopathy |
| topic | central serous chorioretinopathy bevacizumab visual acuity optical coherence tomography. |
| url | http://jbums.org/article-1-10814-en.html |
| work_keys_str_mv | AT mbabaei theeffectofmetabolicdiseasesontheoutcomeofbevacizumabinjectionforcentralserousretinopathy AT hshirafkan theeffectofmetabolicdiseasesontheoutcomeofbevacizumabinjectionforcentralserousretinopathy AT sarasoulinejad theeffectofmetabolicdiseasesontheoutcomeofbevacizumabinjectionforcentralserousretinopathy AT mbabaei effectofmetabolicdiseasesontheoutcomeofbevacizumabinjectionforcentralserousretinopathy AT hshirafkan effectofmetabolicdiseasesontheoutcomeofbevacizumabinjectionforcentralserousretinopathy AT sarasoulinejad effectofmetabolicdiseasesontheoutcomeofbevacizumabinjectionforcentralserousretinopathy |